Fig. 2From: Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trialKaplan–Meier survival analysis curve for time to resolution of symptoms in the ivermectin group (n=32) versus controls (n=32) (p=0.553)Back to article page